Illustration: Brendan Lynch/Axios
VitriVax, a Lyme disease vaccine developer, raised an $87 million Series C, CEO Romulo Colindres exclusively tells Axios Pro.
Why it matters: There is currently no approved Lyme disease vaccine, though Pfizer and Moderna have clinical-stage candidates in their pipelines.